Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Commercial
  • The Rare Journey Needs a Special Pharmacy Partner
  • Commercial

The Rare Journey Needs a Special Pharmacy Partner

Drug Channels

Today's guest post is from Bansi Nagji, Chief Executive Officer at PANTHERx Rare.

CommercialRare DiseaseRead full story

pharminent March 27, 2026 (Last updated: March 30, 2026)

Drug Channels

Today’s guest post is from Bansi Nagji, Chief Executive Officer at PANTHERx Rare.

CommercialRare DiseaseRead full story

Post navigation

Previous: Merck’s deal for Terns sparks debate over a possible biotech bidding war
Next: Novartis targets Xolair successor in buyout of startup Excellergy

Related Stories

  • Commercial

Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1

pharminent August 5, 2026
  • Commercial

Leqembi sales grow again after subcutaneous approvals

pharminent July 29, 2026
  • Commercial

Wegovy pill launches in UK as first daily oral GLP1 for weight management

pharminent July 6, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.